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Abstract
Within pigment-producing cells known as melanocytes, the transcription factor MITF is
intimately involved in regulating genes associated with cell cycle maintenance and melanocyte
differentiation. Research, however, has provided conflicting results on the relationship between
the expression levels of MITF and melanocyte cell fate. To complicate matters, two splice
variants of MITF exist, differing by only 18 base pairs. These variants have been observed at
variable levels of expression in melanocyte and melanoma cells, raising the question as to their
functional purpose. Building upon previous research by the Leachman/Cassidy lab that identified
the redox sensitivity of MITF while additionally establishing a novel relationship between the
antioxidant selenoprotein Thioredoxin Reductase 1 (TR1) and pigment synthesis, this work seeks
to examine the redox sensitivity and function of the MITF splice variants.

Introduction
Melanocytes are specialized cells located primarily within the basal layer of the
epidermis, where they synthesize photoprotective pigments known as melanin (Yamaguchi et al.,
2007). Melanin is a polymer that absorbs ultraviolet (UV) radiation, protecting surrounding
keratinocytes from UV-induced DNA damage by diffusing light energy (Nguyen & Fisher,
2019). Excess UV-induced DNA damage, however, can contribute to the incidence of
melanoma, the cancer which results from the aberrant growth and proliferation of melanocytes.
While melanoma accounts for only 1% of all skin cancer cases, it is responsible for the majority
of skin cancer related deaths (Institute, 2020). Notably, melanocytes are derived from neural
crest cells, a heritage that likely influences the ease of epidermal to mesenchymal transition and
thus enables aggressive metastasis (Larribère & Utikal, 2019). Several genetic mutations are
associated with increased melanoma risk, including the oncogenic BRAFV600E substitution, and
mutations in the CDKN2A tumor suppressor locus (Hodis et al., 2012; Potrony et al., 2015).
Although there are therapeutic treatments currently available, both intrinsic and developed drug
resistance is a hallmark of melanoma (Helmbach et al., 2001), prompting ongoing research into
the regulatory mechanisms of melanocyte and melanoma cell fate.
The microphthalmia associated transcription factor (MITF) is known as the “master
regulator” of melanocyte differentiation and proliferation pathways (Hemesath et al., 1994;
Kawakami & Fisher, 2017). This transcription factor has multiple tissue-specific isoforms that
arise from different enhancer-promoters, resulting in the variable identity of exon 1 (Fuse et al.,
1999). However, only the m-isoform is expressed in select cells of neural crest origin and of
those, most notably in melanocytes, where MITF regulates the expression of enzymes
responsible for melanin synthesis (M. Murakami et al., 2007). Additionally MITF serves as a
transcriptional activator of essential cell survival genes such as MET and BCL2 (Beuret et al.,
2007; McGill et al., 2002) while also regulating the expression of CDKN2A, which inhibits the
cell cycle and thus maintains cell differentiation (Loercher et al., 2005). These connections to
cell cycle regulation have thus made MITF a suspect of oncogenic involvement.
MITF derives its name from the phenotype resulting from mutation of the murine Mi
locus. This phenotype consists of the complete loss of melanocytes as well as the development of
small eyes (microphthalmia) (Kawakami & Fisher, 2017). Mutations in the human MITF
homolog result in variable expression of Waardenburg syndrome type II, characterized by
abnormal pigmentation, hearing loss, and microphthalmia (Tassabehjil et al., 1994). This

transcription factor is a basic helix-loop-helix leucine zipper containing a transactivation domain
which binds the canonical E-box motif, as well as an extended E-box termed the “m-box”
(Hartman & Czyz, 2015). In its active conformation, MITF dimerizes with itself or other bHLHZip transcription factors, specifically TFE3, TFEB, or TFEC (Hemesath et al., 1994).
MITF activation is regulated during development by several lineage-specific factors.
Notably, Sox10 and Pax3 mediate melanocyte cell survival through MITF activation, acting in
synergy to promote transcription (Wellbrock & Arozarena, 2015). The Wnt pathway also alters
MITF expression via β-catenin binding with LEF1, which activates the MITF promoter, an
activity shown to regulate both differentiation and melanocyte growth (Chien et al., 2009;
Eichhoff et al., 2011; Widlund et al., 2002). Intriguingly, MITF has also been shown to interact
with LEF1 to modulate its own expression (Saito et al., 2002).
Canonically, MITF is involved in melanogenesis, the skin’s major defense system against
ultraviolet radiation (Nguyen & Fisher, 2019). UV-induced DNA damage within keratinocytes
activates transcription of POMC via p53. POMC is subsequently post-translationally cleaved into
α-MSH, the signaling molecule for MC1R, a receptor located on the melanocyte plasma
membrane (Hsiao & Fisher, 2014). Activation of MC1R triggers a cAMP signaling cascade that
enables CREB binding to the MITF promoter, activating transcription of MITF (Yamaguchi et
al., 2007). Once translated, MITF activates the expression of Tyrosinase (TYR), Tyrosinase
Related Protein 1 (TYRP1), and Dopachrome Tautomerase (DCT) - enzymes essential for
pigment biosynthesis (Fang, 2002; Jiao et al., 2004; Yasumoto et al., 1995). Additionally, MITF
regulates the expression of PMEL, a melanosome structural protein that enables melanin
deposition, and MLANA, a melanocyte-specific membrane protein (Sitaram & Marks, 2012).
MITF undergoes an array of post translational modifications that alter its activity as a
transcriptional regulator (Wellbrock & Arozarena, 2015). Principally, MITF is phosphorylated at
serine 73 via MAPK, a modification shown to recruit p300, a histone acetyltransferase, which
promotes melanocyte cell growth in a MITF-dependent fashion (Kim et al., 2019; Price et al.,
1998). Phosphorylation of MITF was shown to increase affinity for the tyrosinase promoter,
leading to speculation that phosphorylation could also modulate the transcriptional regulation of
additional MITF target genes (Hemesath et al., 1998). Surprisingly, this modification was also
shown to enable ubiquitin-mediated proteolysis, indicating tightly regulated post-translational
control of MITF function (Wu et al., 2000). MITF is also targeted by SUMOylation at two lysine
residues, a modification shown to repress its transcriptional activity for some but not all target
promoters (H. Murakami & Arnheiter, 2005). A germline mutation that affects the SUMO
binding sequence in MITF has additionally been identified in patients with melanoma (Bertolotto
et al., 2011).
In addition to the known mechanisms of transcriptional and post-translational control,
two splice variants of MITF have been observed at variable expression levels in melanocyte and
melanoma cell lines (Primot et al., 2009). These splice variants differ by an alternative splice
acceptor in exon 6 that controls for the presence or absence (designated + or -18) of 18
nucleotides upstream of the DNA binding domain (Hodgkinson et al., 1993; Steingrimsson et al.,
1994). These 18 nucleotides code for the amino acid sequence ACIFPT (Tachibana et al., 1994).
Although the function of these variants is currently unknown, Primot et al found that the -18
isoform predominates in cultured melanoma cell lines, and variant expression is modulated by
MEK inhibition (Primot et al., 2009). Additionally, MITF +18 expression was shown to elicit

transcription of tyrosinase more efficiently, whereas other research found that this isoform has an
inhibitory effect on DNA synthesis, and subsequently cell proliferation (Bismuth et al., 2005; M.
Murakami et al., 2007).
Our investigation of MITF function coincides with an inquiry of melanocyte response to
oxidative stress. Melanocyte cells are exposed to oxidative stress from a variety of sources,
including the melanin synthesis process which generates hydrogen peroxide, and UV radiation,
which induces reactive oxygen species (ROS) including superoxide anion (Meyskens et al.,
2001). In general, oxidative stress incites a distinct cellular response which can be alleviated by
antioxidant proteins, such as the Thioredoxin/thioredoxin reductase and glutathione/glutaredoxin
redox systems, as well as additional antioxidant programs that are transcriptionally controlled by
Nrf2 and the redox sensor APE-1 (Liu et al., 2009; Tonelli et al., 2018). However, melanoma
cells have been reported to contain higher levels of ROS than normal melanocytes (Policastro et
al., 2009). While increased oxidative stress is expected to increase the DNA mutational load and
subsequent cancer potentiation of a cell, such stress may additionally dysregulate redox-mediated
cell signaling pathways. Consequently, it is suggested that alterations in the redox state of
melanocytes are involved in the pathogenesis of melanoma (Meyskens et al., 2001).
Previous research by Cassidy et al found a positive correlation between melanoma stage
and Thioredoxin reductase 1 (TR1) expression, suggesting that upregulation of this antioxidant
may be a factor in melanoma development (Cassidy et al., 2015). Subsequently, while further
investigating the relationship between TR1 expression and melanocyte behavior, the
Leachman/Cassidy lab found that melanin was significantly reduced after knocking down TR1 in
immortalized melanocytes. This turned attention towards the regulator of pigment biosynthesis MITF.
To understand the role of TR1 in pigmentation, the Leachman/Cassidy lab first examined
the effects of redox stress on the network of cellular antioxidants, including TR1, its substrate
Thioredoxin (TRX), and peroxiredoxin 1 (PRX1), a thiol oxidoreductase known to interact with
TRX via disulfide exchange. To investigate these proteins under redox stress, cells were treated
with varying concentrations of hydrogen peroxide. Following hydrogen peroxide treatment, cells
were supplemented with N-ethylmaleimide (NEM) to covalently modify reduced thiols and
prevent oxidized artifacts, thereby capturing the oxidation states of cellular proteins (GarcíaSantamarina et al., 2014; Hansen & Winther, 2009). Cell lysates were then fractionated by nonreducing SDS-PAGE. By this method, proteins that engage in disulfide bonds with other proteins
are anticipated to appear at higher molecular weights on a western blot, indicative of protein
complexes (Stöcker et al., 2018). To our surprise, probing these blots for MITF showed
unexpected high molecular weight species in melanocytes treated with hydrogen peroxide (figure
1A). Additionally, when the same lysates were run under reducing conditions, MITF was
restored to its expected weight of approximately 54 kD, consistent with the behavior of transient
redox-sensitive complexes (Figure 1B). These experiments revealed that MITF is capable of
forming disulfide linked conjugates under oxidative stress, suggesting that MITF serves a redoxmediated function within the cell. Combined with the observation that pigment synthesis is
reduced in TR1 knockdown cells, these results indicate that MITF responds to TR1 regulation,
potentially in a direct or indirect redox-dependent fashion. Together, these findings point towards
a redox associated role for MITF in melanocyte biology and the development of melanoma.

Heterogeneous expression of MITF in Melanoma cells has complicated the distinction
between MITF and cell fate (Ennen et al., 2015; Goodall et al., 2008). A “rheostat model” has
been suggested for MITF, where low levels of expression correspond to senescence or invasive
properties, and higher expression to proliferation and differentiation tendencies (Goding, 2011).
In line with this model, we hypothesize that a balance between MITF variant expression is
involved in maintaining the associated differentiation and proliferation pathways in normal
melanocytes. With the observation that MITF is sensitive to hydrogen peroxide and additional
evidence that its transcriptional targets are impacted by inhibition of endogenous redox protein
(Kline et al., n.d.) we suggest MITF undergoes a redox-mediated post translational modification
that affects its activity within the cell, thereby attenuating transcriptional targets in accordance
with cellular redox conditions. Furthermore, because the 18 base pairs retained by the +18
isoform encode an additional cysteine residue capable of oxidation, we hypothesize the splice
variants may be differentially responsive to redox conditions, thus affecting their expression,
protein interactions, and/or target genes. Cumulatively, a change in cellular redox state may
therefore affect the expression and functional response of the MITF variants, leading to a
modulated cellular response that may direct melanocytes towards a proliferative, cancerous
phenotype.
To investigate this hypothesis, we designed MITF variant-specific expression vectors and
transfected multiple cell lines to optimize protein expression. Transfected cells were treated with
hydrogen peroxide to induce oxidative stress, and protein was extracted and analyzed under
reducing and non-reducing conditions. The final expression constructs are equipped with dual
tags, enabling co-immunoprecipitation of MITF with any binding partners, and their
identification by mass spectrometry. This will allow us to assess whether the MITF variants
interact with different proteins, potentially in a redox-dependent fashion. While this work
represents only the initial stages of our intended investigation of MITF variant activity, our
preliminary data corroborates earlier findings, and will enable further examination of the
functional characteristics of MITF splice variants.

Figure 1. Western blot of PIG1 melanocytes with hydrogen peroxide treatment courtesy of Dr. Chelsey
Kline, from her paper currently under review. TR1lo cells stably express a siRNA targeting Thioredoxin
reductase 1, while TR1high cells express a control siRNA that does not target a eukaryotic transcript. Cells
were subsequently treated with a 1 min burst of hydrogen peroxide at different concentrations, followed by
treatment with 100 mM NEM to covalently modify reduced thiols. a) Protein lysate run on a non-reducing gel
showcases MITF at high molecular weights (MITF-S-S-X) as well as the anticipated monomeric weight of 54
kD. b) Running the same lysates under reducing conditions shows that MITF is restored to its
anticipated molecular weight of approximately 54 kD upon reduction by BME. A similar response to
hydrogen peroxide is observed by peroxiredoxin 1 (PRX1), which dimerizes under non-reducing conditions
(PRX1-S2, PRX1-S-S2).

Methods and Results
Our initial goal was to isolate expression of the MITF + and – 18 bp variants. We
constructed affinity tagged MITF expression vectors and transfected various cell lines that do not
endogenously express the melanocyte-specific MITF isoform (MITF-m). The MITF - 18
expression plasmid was purchased from Addgene (pCMV Tag4a-MITF-M (wt), #33151). This
plasmid encodes a carboxyl terminal flag tag, as well as a neomycin resistance gene. The MITF
+ 18 variant was constructed by overlap extension PCR to integrate the missing 18 bp sequence
into the pCMV-Tag4a plasmid. We primarily transfected Hela cells, as the endogenous MITF
expression has previously been characterized in this cell line. HeLa cells express the MITF-A, C
and H isoforms, but do not express the m isoform (Fuse et al., 1999; Primot et al., 2009). We
conveniently found that the MITF D9 antibody (Santacruz, sc-515925) although advertised as a
MITF-m specific antibody, additionally detects the MITF-A isoform, confirmed by both western
blot (Supplemental Figure 1, Appendix) and examination of the D9 epitope sequence. In contrast
the MITF C5 antibody (Millipore Sigma, MAB3747-I) appears specific to the MITF-m isoform.

The application of these two antibodies subsequently allowed us to compare the protein levels
from our expression vectors against endogenous MITF levels in HeLa cells.
HeLa cells (ATCC, CCL-2) were transfected using both lipofectamine and Neon
electroporation (ThermoFisher) to determine the best method of transfection. Although HeLa
cells are considered an easily-transfectable cell line, we experienced inconsistent protein
expression using either transfection method. Geneticin aminoglycoside antibiotic (Life
Technologies, #11811023) was used to select for stable expression of MITF following
transfection, however the selection process appeared to affect cell viability, further contributing
to low protein yields and preventing establishment of stable cell lines. While MITF expressing
non-melanocyte cell lines have been generated by other labs, reviewed literature indicates MITF
was only transiently expressed in such experiments. Therefore, we hypothesize that nonmelanocyte cells do not have a favorable response to stable expression of the melanocyte specific
MITF isoform. Additionally, we hypothesized the carboxyl tag itself could be inhibiting protein
detection, given the differences observed when probing the same samples with anti-MITF (C5)
and anti-flag antibodies (Figure 2). Consequently, we later found literature that indicates MITF is
cleaved by caspases to produce a 45 kD amino terminal fragment (Larribere et al., 2005). Such
cleavage by caspases would explain the differences in detection between anti-MITF (C5) and
anti-flag antibodies on the same membranes, as cleavage of the carboxyl terminus would result
in loss of the flag tag. Typically, the melanocyte specific MITF isoform is observed around 54kD
and 60kD on western blots, the higher molecular weight species being attributed to the
phosphorylated form of MITF (Hemesath et al., 1998).

Figure 2. Western blot of HeLa cells transfected with pCMV-Tag4a MITF-m variant plasmids.
Replicate membranes were blotted with anti-flag and anti-MITF C5 antibodies to compare detection
between the two antibodies. a) The anti-flag antibody shows negligible protein expression. b) Results from
the C5 antibody indicate MITF expression, however the -18 variant shows greater expression in
comparison to the +18 variant. Furthermore, an approximately 45 kD band is recognized by the C5, but not
the anti-flag antibody, supporting its identification as an amino terminal fragment of MITF, produced by
caspase cleavage.

Construction and Expression of N-terminal Flag-tagged MITF
To test the hypothesis that the C-terminal tag affects expression of MITF, we constructed
N-terminal flag-tagged expression vectors. The pCMV-Tag2b vector, encoding an amino
terminal flag tag, was a generous gift from Dr. Ping Xing, Oregon Health & Science University.
The MITF variant inserts were isolated from the previous pCMV-Tag4a vectors by digesting
with EcoRI and HindIII restriction enzymes. The pCMV-Tag2B vector was additionally digested
and treated with calf intestine alkaline phosphatase, and both inserts and vector were isolated by
gel electrophoresis on 1% TAE agarose gel. The DNA fragments were excised from the gel and
purified using the QIAquick gel extraction kit (Qiagen, #28704). Overnight ligation at 16°C was
completed using T4 DNA ligase (ThermoFisher, # 15224017) at a 3:1 insert to vector molar
ratio. One Shot TOP10 E. coli (Thermofisher, # C404003) were transformed with the ligated
reaction according to manufacturer’s recommendations. The transformations were plated on LB
plates with kanamycin (50µg/ml), and isolated colonies were selected and grown in 100 mL
volumes of LB liquid culture. Plasmids were then purified from the bacterial cultures using the
Qiagen Endofree plasmid maxi kit (Qiagen, #12362), quantified using a Biotek Synergy H1
microplate reader, and sequenced (Vollum DNA sequencing Core, OHSU).
Transfection with the pCMV-Tag2b MITF variant plasmids was performed using
Lipofectamine 3000 lipid reagent (Fisher Scientific, L3000-08). Lipofectamine 3000 was used
according to manufacturer's recommendations, with Optimem serum free media, P3000 reagent,
and 2.5 µg plasmid. Solutions were added to 6-well plates with 250,000 HeLa cells/well.
Twenty-four hours post transfection, cell media was removed and replaced with either 100µM
H2O2 or PBS for 1 minute. Treatment was then removed and replaced with 100 mM NEM in
PBS and incubated for 5 minutes on ice. Cells were subsequently harvested in lysis buffer (40
mM HEPES- pH7.5, 50 mM NaCl, 1 mM EDTA, 1% Triton X-100) with 100 mM NEM.
Lysates were incubated for 1 hour at 37°C, sonicated, and centrifuged. Protein lysates were
divided into reducing and non-reducing aliquots, whereby reducing samples were heated for 5
minutes at 95℃ in NuPAGE loading buffer (Invitrogen, NP0007) with 𝛽-Mercapthoethanol
(BME) at 1% final concentration. Non-reducing samples were heated in NuPAGE buffer only.
Protein lysates were quantified by BCA protein assay, and 7 ug of protein per sample was run on
4-12% bis-Tris SDS-PAGE gel for 90 minutes at 100 volts. The gel was transferred to a 0.45 µm
PVDF membrane on ice for 60 minutes at 30 volts. Membranes were then blocked in 5% non-fat
dried milk in Tris-buffered saline overnight. Each membrane was blotted with anti-MITF C5,
anti-Flag (Sigma Aldrich, # F1804), and β-actin (Cell Signaling, # F1804) with complementary
secondary antibodies conjugated to horseradish peroxidase (Abcam, ab6789 and ab6721). The
membranes were subsequently exposed with chemiluminescent reagent (ThermoFisher, #34076)
and imaged.
Use of Lipofectamine 3000 reagent was found to increase transfection efficiency over
Neon Electroporation. A time course study of protein expression indicated that 24 hours post
transfection was optimum, having high expression levels without compromising cell viability.
Application of NEM following hydrogen peroxide treatment preserved disulfide conjugated
proteins induced by redox stress, and enabled visualization of protein conjugates on nonreducing gels (Figure 3). MITF was in fact observed at higher molecular weights in hydrogen
peroxide treatment groups on non-reducing gels (Figure 3a), as previously described by Kline et
al. In contrast, running the same protein samples under reducing conditions restores MITF to its

monomeric molecular weight of 54 kD (Figure 3b). On additional reducing gels, MITF
expression was also observed around 45kD (Figure 4). This observation is consistent with the
reports of MITF cleavage by Lariberre et al, which produces a 45kD N-terminal MITF fragment
(Larribere et al., 2005). Because we are hoping to identify binding partners of MITF through
immunoprecipitation and mass spectrometry, cleavage of the protein could compromise efficient
isolation of the entire polypeptide.

Figure 3. Western blot of HeLa cells transfected with N-terminal flag-tagged MITF variants and
treated with hydrogen peroxide. Under non-reducing conditions, MITF appears at high molecular
weights in hydrogen peroxide treatment groups only (MITF-S-S-X), whereas MITF in untreated cells is
observed at its anticipated molecular weight between 50-65 kD (figure 4A). Under reducing conditions,
MITF is restored to its anticipated molecular weight (figure 4B) as expected of transient, disulfide linked
proteins. Probing these blots for Peroxiredoxin 1 (Prx1), a protein known to dimerize via disulfide bonds
(Prx12), shows a similar pattern of high molecular weight species on non-reducing gel.

Figure 4. Hela cells transfected with N-terminal flag-tagged MITF variants, run under reducing
conditions. Twenty-four hours after transfection with lipofectamine 3000 reagent, MITF is observed at two
molecular weights. Probing with either C5 antibody (a) or anti-Flag antibody (b) indicates the presence of
an MITF fragment of approximately 45 kD.

Construction and expression of dual-tagged MITF transfection vector
To ensure isolation of the intact MITF polypeptide during immunoprecipitation, we
designed a dual-tagged expression vector that will enable affinity purification with 2 different
antibodies. A pCMV6-AC-3HA plasmid (Origene, PS100067) encoding a triple hemagglutinin
(HA) carboxyl tag was utilized as the transfection vector. A BsiWI restriction site was
substituted into the pCMV-Tag2B MITF variant plasmids using overlap extension PCR. By this
method, the MITF variant sequences and amino-terminal flag tag could be isolated from the
Tag2B plasmids by restriction digest. The pCMV-Tag2B MITF variant plasmids were amplified
with CMV-F/BsiWI-R and BsiWI-F/T7-F primer pairs (Table 1, appendix) using Phusion Flash
polymerase (Thermofisher, F548S). The reactions were purified using the Purelink PCR
purification kit (Invitrogen, K310001), then the reaction products were amplified together using
the CMV-F/T7-F primer pair. The PCR product was again purified, then digested alongside the
pCMV6-AC-3HA vector using BmtI and BsiWi high fidelity restriction enzymes (NEB, R3658S
and R3553S). The vector was treated with calf intestine alkaline phosphatase, then both inserts
and vector were isolated by gel electrophoresis on 1% TAE agarose gel. After gel extraction and
purification, insert and vector were mixed at a 3:1 molar ratio, treated with T4 DNA ligase, then
incubated for 1 hour at room temperature. Transformation, plasmid purification, and sequencing
were performed as previously described.
M14-/- and WT melanoma cells were transfected with the dual-tagged MITF expression
vectors using lipofectamine 3000 reagent as previously described. The M14-/- cell line is a TR1
knockout generated by Dr. Chelsey Kline using CRISPR/Cas9 technology. RNAseq analysis of
these cells indicates that the melanocyte specific MITF isoform is no longer expressed in these
cells following TR1 knockout (Kline et al., n.d.). Given that WT M14 cells endogenously
express the melanocyte specific MITF isoform, we anticipated these cells would more readily
express MITF variant constructs than HeLa cells. A hydrogen peroxide assay and SDS-PAGE
were run as previously described, with protein lysates fractionated under reducing and nonreducing conditions. Confirming earlier findings, both MITF variants treated with hydrogen
peroxide were observed at high molecular weights on non-reducing gels (Figure 5b). In
comparison, MITF was only observed at its monomeric molecular weight of 54 kD in control
groups without hydrogen peroxide treatment (Figure 5a).

Figure 5. M14 cells transfected with dual-tagged MITF variant plasmids.
a) In control cell lysates fractionated under non-reducing conditions, MITF is primarily observed at its
monomeric molecular weight, between 50-65kD. b) Following treatment with hydrogen peroxide, MITF
is observed at high molecular weights (MITF-S-S-X) under non-reducing conditions. c, d) When the
same cell lysates are run under reducing conditions, MITF is observed only at its monomeric molecular
weight, regardless of treatment group. The restoration of MITF to its monomeric molecular weight
following reduction by BME is indicative of transient, disulfide-linked protein conjugates. Surprisingly,
MITF was not detected in M14 WT cells at this exposure, indicating that expression of the MITF
constructs is much higher than endogenous levels of MITF in M14 cells.

Discussion
Redox modifications have been implicated in the regulation of multiple transcription
factors and signaling pathways, primarily those responsible for regulating antioxidant programs
at the transcriptional level (García-Santamarina et al., 2014). For example, the transcription
factor NF-κB has been identified as redox responsive, interacting with TRX to enable DNA
binding activity (Hayashi et al., 1993; Toledano et al., 1993). Similarly, the activity of the Pax8
transcription factor is dependent on redox state and inhibited by glutathionylation (Cao et al.,
2005; Codutti et al., 2008). The redox effector protein APE-1 (Ref-1) also co-activates
transcription factors via disulfide exchange, activating both NF-κB and Hif1-⍺, a subunit of the
oxygen homeostasis regulator Hif1 (Huang et al., 1996; Tell et al., 2009). Intriguingly, MITF
interacts with some of these redox-sensitive proteins. MITF has been shown to upregulate APE-1
expression in response to cellular redox stress, while MITF additionally binds the Hif1-⍺
promoter and strongly stimulates its transcriptional activity (Buscà et al., 2005; Liu et al., 2009).
These MITF targets implicate MITF as a component of the cellular redox response.
Our work investigates a previously unknown aspect of MITF involvement in the cellular
redox response. Previous work by the Leachman/Cassidy lab found that knockdown of the
antioxidant TR1 results in reduced pigment synthesis in melanocytes, suggesting a novel
association between the TR1antioxidant network and the pigment synthesis pathway. Upon
examination of the cellular effects of TR1 knockdown under hydrogen peroxide-induced redox
stress, MITF was observed to form disulfide linked conjugates after fractionation of cell lysates
by non-reducing SDS-PAGE, illustrating its redox sensitivity. Together these findings support
the hypothesis that MITF may be regulated by TR1 in a redox-dependent fashion, altering its
transcriptional activity. While we suggest a discrete function for MITF redox sensitivity,
additional research must be undertaken to delineate the effects of redox modification on MITF
regulated genes or protein targets. In addition to the proposed redox-dependent functionality of
MITF, we hypothesize the two MITF splice variants respond differently to redox regulation,
according to the presence or absence of an additional cysteine residue. These variants may serve
different functions in the cell, modulating cell fate according to cellular redox conditions.
To investigate the redox sensitivity of the MITF variants in vivo, we constructed affinity
tagged MITF variant vectors and transfected mutant melanoma and non-melanocyte cell lines.
Treatment of cells with hydrogen peroxide followed by free thiol quenching with NEM allowed
us to identify high molecular weight MITF species on non-reducing SDS-PAGE that were not
present under reducing conditions. This is indicative of transient, disulfide-linked protein
conjugates. However, both variants engaged in these redox-mediated conjugates, leading us to
conclude that analysis of MITF by western blots cannot distinguish differences in redox activity
between the two variants. Given that the +18 variant retains an additional cysteine residue, it is
plausible this variant responds more readily to redox regulation. In this fashion, the -18 variant
could be less sensitive to cellular redox conditions, and its overexpression could serve as a
mechanism of cellular escape from redox regulation, potentially driving a cancerous phenotype.
To delineate these theoretical functions, we intend to perform co-immunoprecipitation of the
MITF variants and assess interacting proteins by mass spectrometry. This will help elucidate
whether the splice variants interact with different proteins in a redox-mediated fashion,
contributing to differential activation of downstream targets.

Given the endogenous redox stress within melanocytes and reported increase in ROS in
melanomas, an explicit response to ROS is required to maintain melanocyte homeostasis.
Although MITF redox sensitivity has only been preliminarily identified, confirming this novel
mechanism of MITF regulation and its effect on cellular phenotype will help elucidate the multifaceted role of MITF in melanocyte cell fate. MITF is regulated by multiple activation pathways
and post translational modifications, contributing to its range of expression levels in melanocyte
and melanoma cells. Although levels of MITF expression have been linked to a spectrum of
cellular behavior, the implications of MITF splice variant expression have not been extensively
investigated. While we are exploring the role of these splice variants in the melanocyte specific
MITF isoform, these variants have been additionally reported in other MITF isoforms (M.
Murakami et al., 2007). Differential response of the splice variants to redox regulation could
serve as an additional mechanism of regulation in tissues that express these other MITF
isoforms. Consequently, understanding the comparative function of the MITF splice variants will
illuminate their role in cell fate, contributing to our understanding of cellular regulation in
melanocytes and melanomas.

Appendix

Table 1. Primers used for overlap-extension PCR
CMV-F

5’ TAGTCATCGCTATTACCATGGTGATGC

BsiWI-F 5’ GCACACTTGTCGTACGATCGATACCG
BsiWI-R 5’ CGGTATCGATCGTACGACAAGTGTGC
T7-F

5’ CGAGTGAATTGTAATACGACTCACTATAGGG

Supplemental Figure 1. Comparison of C5 and D9 antibodies in M14-/- and WT cells.
The anti-MITF C5 and D9 antibodies show differences in MITF detection between M14 WT and TR1
knockout (MT) cells. C5 fails to identify MITF expression in two knockout lines (Ck3-98-8(5) and
(11)). RNAseq analysis confirms these lines lack MITF-m expression but retain MITF-A expression.
Additional analysis of the D9 epitope sequence confirms it is found in both the MITF-A and m
isoforms, explaining why D9 detects MITF in those cells where MITF-m is not expressed.
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